The EP1 antagonist used in this study, SC-51089, has been demonstrated to reduce infarct size and behavioral deficits in both transient24, 31 and permanent31 models of ischemic stroke; with efficacy in both male and female mice and a wide window of therapeutic administration31. The gene discussed is PTGER1; the disease is ischemic stroke.